Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009004 | 0.78 | ALDH1A1 (0.35) | ALDH1A1LMNANPSR1 | |
| SCHEMBL20009033 | 0.78 | ALDH1A1 (0.35) | ALDH1A1LMNANPSR1 | |
| SCHEMBL26241586 | 0.71 | KAT2B (0.35) | ALDH1A1LMNANPSR1 | |
| SCHEMBL20012529 | 0.71 | KAT2B (0.35) | ALDH1A1LMNANPSR1 | |
| SCHEMBL26241549 | 0.71 | KAT2B (0.35) | ALDH1A1LMNANPSR1 | |
| SCHEMBL20012734 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNANPSR1 | |
| SCHEMBL20009032 | 0.66 | SLC6A7 (0.38) | ALDH1A1LMNAGLANPSR1 | |
| SCHEMBL18081206 | 0.62 | OPRM1 (0.45) | HTR1A | |
| SCHEMBL18705086 | 0.60 | EGLN1 (0.44) | ALDH1A1NPSR1 | |
| SCHEMBL9963401 | 0.60 | LMNA (0.45) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HTR1A 2791/4885ALDH1A1 3032/4885LMNA 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.